Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
Stock Information
Featured Bugs
Aspergillus fumigatus
 more...
 
Welcome to Basilea
 
 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Its fully integrated research and development operations are currently focused on antibiotics and antifungals, as well as on the development of dermatology and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting.
 
Basilea is currently marketing Toctino® (alitretinoin), the only approved treatment for severe chronic hand eczema unresponsive to potent topical steroids, in Denmark, France, Germany, Switzerland and the United Kingdom and has appointed Almirall, S.A. as its distributor for Toctino® in other selected European markets and Mexico. The company has entered into a global partnership with Astellas Pharma Inc. for its phase III compound isavuconazole, a potential best-in-class azole antifungal, for the treatment of life-threatening invasive fungal infections. Full rights to ceftobiprole, the first approved anti-MRSA broad-spectrum cephalosporin antibiotic, for the treatment of potentially life-threatening resistant bacterial infections, will be transferred from Cilag GmbH International, a Johnson & Johnson company, back to Basilea.
 
News
 
 
Language
 
Friday, July 30. 2010
 
Basel, Switzerland, July 30, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that first results from the TOCCATA observational study were presented at the 22nd Fortbildungswoche für praktische Dermatologie und Venerologie in Munich, Germany. TOCCATA was designed to investigate the clinical profile of Toctino® (alitretinoin) under daily practice conditions in severe chronic hand eczema (CHE) patients in Germany.
 
more...
 
Friday, June 25. 2010
 
Basel, Switzerland, June 25, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that following a request for re-examination from the Applicant Janssen-Cilag International NV (Janssen-Cilag), a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI).
 
more...
 
Friday, June 25. 2010
 
Basel, Switzerland, June 25, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that its partner Astellas Pharma Inc. (TSE:4503) has initiated the formal process to allow continuation of patient recruitment into the phase III clinical studies of isavuconazole for the treatment of life-threatening invasive fungal infections. Certain study protocol amendments have been implemented and the phase III program will be expanded to include more patients.
 
more...
 
Tuesday, June 15. 2010
 
Basel, Switzerland, June 15, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that Basilea Pharmaceutica International Ltd. has entered into an exclusive distribution agreement with Almirall, S.A. for Basilea's Toctino® (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, in selected European markets and Mexico.
 
more...
 
Info
 
 
 

IDSA
Infectious Diseases
Society of America
 
National Eczema Association
for Science and Education
 
Doctorfungus